C4 Therapeutics (CCCC) Accumulated Expenses (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Accumulated Expenses of $9.8 million for Q1 2026, down 22.19% year-over-year from $12.6 million in Q1 2025, and down 26.17% quarter-over-quarter from $13.3 million in Q4 2025.
C4 Therapeutics (CCCC) Accumulated Expenses (2019 - 2026) Analysis & Trends
C4 Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $9.8 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 22.19% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (down 22.19% YoY), while the FY2025 annual figure was $13.3 million, down 31.24% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $9.8 million, down from $13.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $20.6 million in Q4 2023, with the low at $9.8 million in Q1 2026.
- The 5-year median for Accumulated Expenses is $15.4 million (2024), against an average of $14.9 million.
- The sharpest annual moves came in 2022 and 2024: Accumulated Expenses surged 615.12% in 2022, then slumped 33.03% in 2024.
- C4 Therapeutics' Accumulated Expenses stood at $19.8 million in 2022, then grew by 4.36% to $20.6 million in 2023, then dropped by 6.14% to $19.4 million in 2024, then slumped by 31.24% to $13.3 million in 2025, then slipped by 26.17% to $9.8 million in 2026.
- Business Quant data shows CCCC's Accumulated Expenses at $9.8 million in Q1 2026, $13.3 million in Q4 2025, and $11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.79 Mn |
| Mar 31, 2026 | 9.83 Mn |
| Dec 31, 2025 | 13.31 Mn |
| Sep 30, 2025 | 11.27 Mn |
| Jun 30, 2025 | 13.55 Mn |
| Mar 31, 2025 | 12.63 Mn |
| Dec 31, 2024 | 19.36 Mn |
| Sep 30, 2024 | 15.39 Mn |
| Jun 30, 2024 | 11.20 Mn |
| Mar 31, 2024 | 12.89 Mn |
| Dec 31, 2023 | 20.63 Mn |
| Sep 30, 2023 | 15.48 Mn |
| Jun 30, 2023 | 16.73 Mn |
| Mar 31, 2023 | 16.30 Mn |
| Dec 31, 2022 | 19.77 Mn |
| Sep 30, 2022 | 17.94 Mn |
| Jun 30, 2022 | 16.96 Mn |
| Mar 31, 2022 | 9.84 Mn |
| Dec 31, 2021 | 13.61 Mn |
| Sep 30, 2021 | 11.47 Mn |